David Gray

David is an innovative and successful pharmacologist with a vocational drive to discover novel drugs. He has wide ranging expertise across the drug discovery process having devised successful target and hit validation strategies, guided lead identification and compound optimisation and made significant contribution to the selection of 10 clinical candidates across multiple disease areas. This includes a marketed drug, Veramyst.

David has a strong background in pharmacology associated with drug discovery with over 15 years’ experience at Wellcome, GlaxoWellcome and GSK where he established a track record of proposing and critically assessing new targets for drug discovery and repurposing of existing molecules. He has experience in all aspects of early drug discovery including screen design, compound triaging strategies and defining mechanism of action of compounds. He has applied this to a number of target families of receptors including G protein coupled receptors, integrins, nuclear hormone receptors, as well as enzymes such as kinases and proteases. In each of these families he has driven innovative and pragmatic changes in approach and technologies, delivering multiple pre-clinical and clinical candidates. At Dundee, David has continued to propose targets in both the disease of the developing world and innovative targets portfolios and works closely with a number of Principal Investigators within the UK and abroad to develop target validation strategies.